The Times Australia
Google AI
The Times News

.

Scott Morrison to announce two new COVID vaccine deals

  • Written by The Conversation

The government has secured deals for two further COVID-19 vaccines, taking its portfolio of agreements to four.

Under the latest agreements, to be announced by Scott Morrison on Thursday, Novavax would supply 40 million vaccine doses and Pfizer/BioNTech would provide 10 million doses.

The Novavax and Pfizer/BioNTech vaccines are expected to be available in Australia from early to mid next year, subject to the success of trials and the needed approvals.

This brings the government’s vaccine investment to more than $3.2 billion, with a total of 134 million doses.

Morrison, while cautioning that there was no assurance of an effective vaccine, said: “By securing multiple COVID-19 vaccines we are giving Australians the best shot at early access to a vaccine, should trials prove successful.

"We aren’t putting all our eggs in one basket and we will continue to pursue further vaccines should our medical experts recommend them.

"There are no guarantees that these vaccines will prove successful, however our strategy puts Australia at the front of the queue, if our medical experts give the vaccines the green light.”

The earlier vaccine agreements involve the University of Queensland/CSL and Oxford/AstraZeneca.

People are likely to need two doses of Novavax Inc’s vaccine, hence the 40 million doses. The vaccine, if it is found safe and effective, would be expected to arrive from early next year. It would be manufactured in the United States and the Czech Republic.

Novavax’s vaccine candidate began phase three clinical trials in the United Kingdom in September.

Under the other new agreement, the vaccine Pfizer and BioNTech are jointly developing would also be expected early next year, if the vaccine – now in phase three clinical trials – passes muster. It would be manufactured in the US, Belgium and Germany.

The Pfizer/BioNTech is a messenger ribonucleic acid (mRNA) type vaccine and the Novovax vaccine is a protein type vaccine.

Australia’s COVID-19 vaccine portfolio now has two protein vaccines and one mRNA and one viral vector type vaccine.

Health Minister Greg Hunt said: “The goal and the expectation is that Australians who sought vaccination will be vaccinated within 2021.”

Workers in health and aged care, and older people and others most vulnerable to COVID would have first access.

Vaccination places would initially include GPs, GP respiratory clinics, state and territory vaccination sites and workplaces such as aged care facilities.

The vaccine would be free and not mandatory.

The federal government is consulting with the states and territories, medical experts and industry peak bodies about the initial roll-out of the vaccination program early next year.

Internationally, Australia has also joined the COVAX facility, which would provide access to a large portfolio of vaccination candidates and manufactures around the world for up to half of the Australian population.

Read more https://theconversation.com/scott-morrison-to-announce-two-new-covid-vaccine-deals-149458

Times Magazine

With Nvidia’s second-best AI chips headed for China, the US shifts priorities from security to trade

This week, US President Donald Trump approved previously banned exports[1] of Nvidia’s powerful ...

Navman MiVue™ True 4K PRO Surround honest review

If you drive a car, you should have a dashcam. Need convincing? All I ask that you do is search fo...

Australia’s supercomputers are falling behind – and it’s hurting our ability to adapt to climate change

As Earth continues to warm, Australia faces some important decisions. For example, where shou...

Australia’s electric vehicle surge — EVs and hybrids hit record levels

Australians are increasingly embracing electric and hybrid cars, with 2025 shaping up as the str...

Tim Ayres on the AI rollout’s looming ‘bumps and glitches’

The federal government released its National AI Strategy[1] this week, confirming it has dropped...

Seven in Ten Australian Workers Say Employers Are Failing to Prepare Them for AI Future

As artificial intelligence (AI) accelerates across industries, a growing number of Australian work...

The Times Features

I’m heading overseas. Do I really need travel vaccines?

Australia is in its busiest month[1] for short-term overseas travel. And there are so many thi...

Mint Payments partners with Zip Co to add flexible payment options for travel merchants

Mint Payments, Australia's leading travel payments specialist, today announced a partnership with ...

When Holiday Small Talk Hurts Inclusion at Work

Dr. Tatiana Andreeva, Associate Professor in Management and Organisational Behaviour, Maynooth U...

Human Rights Day: The Right to Shelter Isn’t Optional

It is World Human Rights Day this week. Across Australia, politicians read declarations and clai...

In awkward timing, government ends energy rebate as it defends Wells’ spendathon

There are two glaring lessons for politicians from the Anika Wells’ entitlements affair. First...

Australia’s Coffee Culture Faces an Afternoon Rethink as New Research Reveals a Surprising Blind Spot

Australia’s celebrated coffee culture may be world‑class in the morning, but new research* sugge...

Reflections invests almost $1 million in Tumut River park to boost regional tourism

Reflections Holidays, the largest adventure holiday park group in New South Wales, has launched ...

Groundbreaking Trial: Fish Oil Slashes Heart Complications in Dialysis Patients

A significant development for patients undergoing dialysis for kidney failure—a group with an except...

Worried after sunscreen recalls? Here’s how to choose a safe one

Most of us know sunscreen is a key way[1] to protect areas of our skin not easily covered by c...